Alzheimer Disease Clinical Trials in Maitland, Florida

8 studies are recruiting for alzheimer disease in Maitland, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 1622, Maitland, Florida

   Locations

   162 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011732 on ClinicalTrials.gov

2. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

   This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

   Stage

   Phase 2

   Ages

   55 to 90

   Site

   ClinCloud, Maitland, Florida

   Locations

   78 in total

   Run by

   Celgene

   See if you can join NCT06808984 on ClinicalTrials.gov

3. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

   This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

   Stage

   Phase 2

   Ages

   55 and older

   Site

   K2 Medical Research, Maitland, Florida

   Locations

   67 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06540833 on ClinicalTrials.gov

4. A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

   The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of…

   Stage

   Phase 1

   Ages

   50 to 85

   Site

   K2 Medical Research, LLC, Maitland, Florida

   Locations

   10 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06297590 on ClinicalTrials.gov

5. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   K2 Medical Research ORLANDO, Maitland, Florida

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

6. A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

   The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). …

   Stage

   Phase 1

   Ages

   45 to 85

   Site

   K2 Medical Research, Maitland, Florida

   Locations

   13 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06657768 on ClinicalTrials.gov

7. [18F]PI-2620 Phase 3 Histopathological Study

   This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after de…

   Stage

   Phase 3

   Ages

   50 and older

   Site

   K2 Medical Research, Maitland, Florida

   Locations

   25 in total

   Run by

   Lantheus Biosciences Ltd.

   See if you can join NCT05641688 on ClinicalTrials.gov

8. Clinical Trial on Agitation in Alzheimer's Dementia

   The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

   Stage

   Phase 2

   Ages

   60 and older

   Site

   ClinCloud, LLC, Maitland, Florida

   Locations

   31 in total

   Run by

   IGC Pharma, LLC

   See if you can join NCT05543681 on ClinicalTrials.gov